Ajax Therapeutics Acquired by Eli Lilly | Healthcare M&A Deal

Eli Lilly has acquired Ajax Therapeutics, a pharmacy business in New York and Massachusetts, for $2.3 billion. Eli Lilly acquisitions focus on oncology and immune disease therapeutics, and Ajax Therapeutics is developing a next-generation JAK inhibitor candidate for myelofibrosis and related indications. Ajax’s AJ1-11095 is designed to bind an inactive JAK conformation to target resistance and improve durability for patients who discontinue current JAK therapies. The Eli Lilly acquisitions are a strategic acquisition and healthcare M&A deal with up to $2.3 billion in guaranteed cash and milestone payments tied to clinical and regulatory outcomes.